AMLX
Amylyx Pharmaceuticals Inc
30.60$
-7.3%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +10.9% | -19.3% | -20.4% | -24.5% | -22.8% | +13.4% | -11.4% | +86.4% | -8.3% | -11.7% | -9.9% | |
| – | +7.0% | -11.6% | -20.4% | -24.9% | -22.8% | +14.1% | -13.5% | +89.1% | -8.4% | -11.9% | -10.1% | |
| – | +25.8% | +0.2% | -56.0% | -4.2% | +7.7% | -22.8% | -2.8% | +287.7% | +0.7% | +1.1% | -78.5% | |
| – | +4.6% | +0.5% | -17.0% | -24.3% | -24.7% | +15.6% | -11.4% | +90.2% | -7.9% | -11.7% | -10.4% | |
| – | +36.4% | -49.2% | -79.9% | -57.7% | -74.2% | -32.9% | -32.3% | +14.3% | -62.1% | +13.6% | – | |
| – | +18.4% | -100.0% | -100.0% | – | – | – | – | – | – | – | – | |
| – | +74.4% | +10.7% | -23.8% | -23.1% | -47.0% | -36.8% | +46.3% | +15.1% | -10.9% | -25.4% | +24.2% | |
| – | +79.8% | +11.7% | -23.5% | -23.1% | -47.3% | -36.9% | +19.5% | +20.4% | -12.0% | -29.6% | +32.5% | |
| – | +2.5% | +2.4% | +2.5% | -16.8% | -23.0% | -30.5% | -37.0% | +47.5% | +28.3% | -8.3% | -12.7% | |
| – | +246.3% | -2.8% | -76.9% | -70.0% | +97.6% | +63.7% | -31.5% | +62.1% | -34.1% | +0.3% | +56.8% | |
| – | +3.6% | -25.1% | -19.5% | -24.9% | -16.0% | +22.2% | -16.7% | +97.8% | -8.1% | -10.5% | -12.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -0.8% | -1.9% | +0.3% | +0.1% | +0.7% | +24.9% | +4.0% | +4.7% | +1.3% | +16.9% | +0.6% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.